Bolag Altan1, Takehiko Yokobori2, Munenori Ide3, Erito Mochiki4, Yoshitaka Toyomasu1, Norimichi Kogure1, Akiharu Kimura1, Keigo Hara1, Tuya Bai1, Pinjie Bao1, Masaki Suzuki1, Kyoichi Ogata1, Takayuki Asao5, Masahiko Nishiyama6, Tetsunari Oyama3, Hiroyuki Kuwano1. 1. Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Gunma, Japan. 2. Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Gunma, Japan. bori45@gunma-u.ac.jp. 3. Department of Diagnostic Pathology, Graduate School of Medicine, Gunma University, Maebashi, Gunma, Japan. 4. Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan. 5. Department of Oncology Clinical Development, Graduate School of Medicine, Gunma University, Maebashi, Gunma, Japan. 6. Department of Molecular Pharmacology and Oncology, Graduate School of Medicine, Gunma University, Maebashi, Gunma, Japan.
Abstract
BACKGROUND: Metastatic and refractory gastric cancer (GC) are associated with a poor prognosis; therefore, the identification of prognostic factors and chemosensitivity markers is extremely important. Protein arginine methyltransferase 1 (PRMT1) may play a role in chemosensitivity/apoptosis induction via activation of the tumor suppressor forkhead box O1 (FOXO1). The purpose of this study was to clarify the expression of and relationship between PRMT1 and FOXO1 to evaluate the applicability of PRMT1 as a prognostic marker and a therapeutic tool in GC. METHODS: We investigated the clinical and functional significance of PRMT1 and FOXO1 in 195 clinical GC samples using immunohistochemistry. We performed suppression analysis of PRMT1 using small interfering RNA to determine the biological roles of PRMT1 in chemosensitivity. RESULTS: PRMT1 and FOXO1 in GC samples were predominantly expressed in the nucleus. Patients with lower PRMT1 expression (n = 131) had suppressed nuclear accumulation of FOXO1, higher recurrence after adjuvant chemotherapy, and poorer prognosis than those with higher PRMT1 expression (n = 64). PRMT1 downregulation in GC cells by RNA interference inhibited cisplatin and 5-fluorouracil sensitivity. The expression of phosphorylated FOXO1 and phosphorylated BCL-2 antagonist of cell death was upregulated in PRMT1 small interfering RNA groups. CONCLUSION: Our data suggest that the evaluation of PRMT1 expression in GC is a useful predictor of poor prognosis and recurrence after adjuvant chemotherapy. Moreover, these data suggest that PRMT1 is a promising therapeutic tool for overcoming refractory GC.
BACKGROUND: Metastatic and refractory gastric cancer (GC) are associated with a poor prognosis; therefore, the identification of prognostic factors and chemosensitivity markers is extremely important. Protein arginine methyltransferase 1 (PRMT1) may play a role in chemosensitivity/apoptosis induction via activation of the tumor suppressor forkhead box O1 (FOXO1). The purpose of this study was to clarify the expression of and relationship between PRMT1 and FOXO1 to evaluate the applicability of PRMT1 as a prognostic marker and a therapeutic tool in GC. METHODS: We investigated the clinical and functional significance of PRMT1 and FOXO1 in 195 clinical GC samples using immunohistochemistry. We performed suppression analysis of PRMT1 using small interfering RNA to determine the biological roles of PRMT1 in chemosensitivity. RESULTS:PRMT1 and FOXO1 in GC samples were predominantly expressed in the nucleus. Patients with lower PRMT1 expression (n = 131) had suppressed nuclear accumulation of FOXO1, higher recurrence after adjuvant chemotherapy, and poorer prognosis than those with higher PRMT1 expression (n = 64). PRMT1 downregulation in GC cells by RNA interference inhibited cisplatin and 5-fluorouracil sensitivity. The expression of phosphorylated FOXO1 and phosphorylated BCL-2 antagonist of cell death was upregulated in PRMT1 small interfering RNA groups. CONCLUSION: Our data suggest that the evaluation of PRMT1 expression in GC is a useful predictor of poor prognosis and recurrence after adjuvant chemotherapy. Moreover, these data suggest that PRMT1 is a promising therapeutic tool for overcoming refractory GC.
Authors: Masanori Yoshimatsu; Gouji Toyokawa; Shinya Hayami; Motoko Unoki; Tatsuhiko Tsunoda; Helen I Field; John D Kelly; David E Neal; Yoshihiko Maehara; Bruce A J Ponder; Yusuke Nakamura; Ryuji Hamamoto Journal: Int J Cancer Date: 2011-02-01 Impact factor: 7.396
Authors: Jinju Park; Young San Ko; Jiyeon Yoon; Min A Kim; Jong-Wan Park; Woo Ho Kim; Youngsun Choi; Ji Hun Kim; Younghee Cheon; Byung Lan Lee Journal: Gastric Cancer Date: 2013-11-08 Impact factor: 7.370
Authors: Wei Hong; Jingyang Li; Charles A Laughton; Lee Fah Yap; Ian C Paterson; Hao Wang Journal: J Mol Graph Model Date: 2014-06-04 Impact factor: 2.518
Authors: Youngsun Choi; Jinju Park; Yiseul Choi; Young San Ko; Da-Ae Yu; Younghoon Kim; Jung-Soo Pyo; Bo Gun Jang; Min A Kim; Woo Ho Kim; Byung Lan Lee Journal: BMC Gastroenterol Date: 2016-06-06 Impact factor: 3.067
Authors: Joe Abdo; Christopher S Wichman; Nicholas E Dietz; Pawel Ciborowski; John Fleegel; Sumeet K Mittal; Devendra K Agrawal Journal: Front Oncol Date: 2018-05-09 Impact factor: 6.244